Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(R)-(+)9B-(3-methyl)phenyl-2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-one is a synthetic small molecule belonging to the isoindolone class of organic compounds. It has been studied as a non-nucleoside reverse transcriptase inhibitor (NNRTI), specifically targeting HIV‑1 reverse transcriptase. Structural studies have shown it binds to the allosteric NNRTI binding pocket of HIV‑1 reverse transcriptase and inhibits its activity by inducing conformational changes that prevent viral DNA synthesis. The compound is primarily used in research settings and has not been approved for clinical use.[1][2][7][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (R)-(+)9B-(3-methyl)phenyl-2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-one.